Zoledronic acid has received a positive approval recommendation in Europe for use in the treatment of osteoporosis, putting it one step closer to final approval by the European Commission. The once-yearly intravenous medication is a bisphosphonate that inhibits the process of bone breakdown.

Zoledronic acid is now FDA-approved in the U.S. only for the treatment of other conditions, such as Paget's disease, but favorable results in use treating osteoporosis were recently reported by the New England Journal of Medicine.

More info is available at:

http://www.therapeuticsdaily.com/news/article.cfm?contentValue=1436688&contentType=sentryarticle&chann